RGNX — Regenxbio Income Statement
0.000.00%
Last trade - 00:00- $418.07m
- $375.01m
- $170.44m
Annual income statement for Regenxbio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 470 | 113 | 90.2 | 83.3 | 170 |
| Cost of Revenue | |||||
| Gross Profit | 419 | 58.2 | 53 | 49.8 | 150 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 310 | 376 | 358 | 317 | 332 |
| Operating Profit | 160 | -263 | -268 | -233 | -161 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 141 | -280 | -264 | -227 | -194 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 128 | -280 | -263 | -227 | -194 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 128 | -280 | -263 | -227 | -194 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 128 | -280 | -263 | -227 | -194 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 2.91 | -6.5 | -6.02 | -4.54 | -3.76 |